Details

Autor(en) / Beteiligte

• MIRANDA, Roberto N
• ALADILY, Tariq N
• SHIFRIN, David A
• O'MALLEY, Dennis P
• CHEAH, Chan Y
• BACCHI, Carlos E
• GUALCO, Gabriela
• SHIYONG LI
• KEECH, John A
• HOCHBERG, Ephram P
• CARTY, Matthew J
• HANSON, Summer E
• PRINCE, H. Miles
• MUSTAFA, Eid
• SANCHEZ, Steven
• MANNING, John T
• XU-MONETTE, Zijun Y
• MIRANDA, Alonso R
• FOX, Patricia
• BASSETT, Roland L
• CASTILLO, Jorge J
• BELTRAN, Brady E
• DE BOER, Jan Paul
• KANAGAL-SHAMANNA, Rashmi
• CHAKHACHIRO, Zaher
• DONGJIU YE
• CLARK, Douglas
• YOUNG, Ken H
• MEDEIROS, L. Jeffrey
• DE JONG, Daphne
• FAYAD, Luis E
• AMIN, Mitual B
• HAIDERI, Nisreen
• BHAGAT, Govind
• BROOKS, Glen S

Titel

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

Ist Teil von

• Journal of clinical oncology, 2014-01, Vol.32 (2), p.114-120

Ort / Verlag

Alexandria, VA: American Society of Clinical Oncology

Erscheinungsjahr

2014

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clinicopathologic entity that usually presents as an effusion-associated fibrous capsule surrounding an implant. Less frequently, it presents as a mass. The natural history of this disease and long-term outcomes are unknown. We reviewed the literature for all published cases of breast implant-associated ALCL from 1997 to December 2012 and contacted corresponding authors to update clinical follow-up. The median overall survival (OS) for 60 patients was 12 years (median follow-up, 2 years; range, 0-14 years). Capsulectomy and implant removal was performed on 56 of 60 patients (93%). Therapeutic data were available for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who did not receive chemotherapy, 12 patients opted for watchful waiting and four patients received radiation therapy alone. Thirty-nine (93%) of 42 patients with disease confined by the fibrous capsule achieved complete remission, compared with complete remission in 13 (72%) of 18 patients with a tumor mass. Patients with a breast mass had worse OS and progression-free survival (PFS; P = .052 and P = .03, respectively). The OS or PFS were similar between patients who received and did not receive chemotherapy (P = .44 and P = .28, respectively). Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission. Proper management for these patients may be limited to capsulectomy and implant removal. Patients who present with a mass have a more aggressive clinical course that may be fatal, justifying cytotoxic chemotherapy in addition to removal of implants.